NCT00978432 - Epigenetic Modulation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

April 30, 2015

Study Completion Date

March 31, 2016

Conditions

Diffuse Large B-cell Lymphoma

Interventions

DRUG

RAD001

10 mg/day for Part 1 of the trial

DRUG

LBH589

40 mg on Monday, Wednesday and Friday weekly for Part 1 of the trial

DRUG

Doublet (RAD001 and LBH589)

RAD001 7.5 mg by mouth daily and LBH589 15 mg by mouth on Monday/Wednesday/Friday during Part 2.

Trial Locations (1)

Duke University Medical Center, Durham